Integrated DNA Technologies, Inc., Coralville, Iowa 52241, USA.
Mol Ther. 2012 Mar;20(3):483-512. doi: 10.1038/mt.2011.263. Epub 2011 Dec 20.
RNA interference (RNAi) has been extensively employed for in vivo research since its use was first demonstrated in mammalian cells 10 years ago. Design rules have improved, and it is now routinely possible to obtain reagents that suppress expression of any gene desired. At the same time, increased understanding of the molecular basis of unwanted side effects has led to the development of chemical modification strategies that mitigate these concerns. Delivery remains the single greatest hurdle to widespread adoption of in vivo RNAi methods. However, exciting advances have been made and new delivery systems under development may help to overcome these barriers. This review discusses advances in RNAi biochemistry and biology that impact in vivo use and provides an overview of select publications that demonstrate interesting applications of these principles. Emphasis is placed on work with synthetic, small interfering RNAs (siRNAs) published since the first installment of this review which appeared in 2006.
RNA 干扰 (RNAi) 自 10 年前首次在哺乳动物细胞中得到证实以来,已被广泛用于体内研究。设计规则得到了改进,现在通常可以获得抑制所需任何基因表达的试剂。与此同时,对不良副作用分子基础的认识不断提高,导致了化学修饰策略的发展,减轻了这些担忧。传递仍然是广泛采用体内 RNAi 方法的最大障碍。然而,令人兴奋的进展已经取得,新的传递系统的发展可能有助于克服这些障碍。这篇综述讨论了影响体内应用的 RNAi 生物化学和生物学方面的进展,并概述了一些展示这些原理有趣应用的精选出版物。重点是 2006 年首次出现本综述以来发表的关于合成小干扰 RNA(siRNA)的工作。